Table 1.
Baseline characteristics of 72 COPD exacerbation patients requiring emergency department admissions
| Baseline characteristics (n=72) | |
|---|---|
| Age, year | 75.17±7.94 |
| Male, n (%) | 72 (100) |
| BMI, kg/m2 | 21.98±4.57 |
| FEV1/FVC ratio, % | 55.34±9.86 |
| FEV1 % predicted normal, % | 40.12±15.70 |
| GOLD 1, n (%) | 1 (1.39) |
| GOLD 2, n (%) | 13 (18.06) |
| GOLD 3, n (%) | 43 (59.72) |
| GOLD 4, n (%) | 15 (20.83) |
| FVC% predicted normal, % | 50.15±17.10 |
| Tobacco use, pack-years | 61.29±30.69 |
| Current smoker, n (%) | 33 (45.8) |
| Ex-smoker, n (%) | 39 (54.2) |
| ICS + LABA, n (%) | 58 (80.56) |
| Inhaled anticholinergics, n (%) | 56 (77.78) |
| Oral corticosteroid, n (%) | 14 (19.44) |
| Short term oral antibiotics, n (%) | 7 (9.7) |
| Oral methylxanthines, n (%) | 52 (72.22) |
| Anthonisen criteria ≥2, n (%) | 52 (72.22) |
| WBC, 109/L | 10.52±4.19 |
| CRP, mg/L | 34.97±48.02 |
| PCT, ng/mL | 0.2012±0.4315 |
| Exacerbation in the sequential 1 year, n (exacerbation/person/year) | 38 (0.52) |
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GOLD, Global Initiatives for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting beta-agonists; PCT, procalcitonin; WBC, white blood cell.